UCB has non-exclusive rights for research and development using ELEVECTA producer cell lines for specific transgenes selected by UCB. The agreement also grants UCB options to obtain licenses for use of the ELEVECTA producer cell lines in commercial manufacturing of potential AAV gene therapy products, and for the internal use of the ELEVECTA Technology at UCB to generate new producer cell lines.
CEVEC is eligible for license fees, clinical and regulatory milestone payments, as well as royalties on potential future net sales. Financial details were not disclosed.
“We are very pleased to have UCB embarking on the ELEVECTA® Technology enabling them to use the platform for scalable, robust and efficient manufacturing of gene therapy vectors,” said Dr. Nicole Faust, Chief Executive Officer of CEVEC. “This license agreement represents a further step towards establishing ELEVECTA® as the future AAV manufacturing standard. With more and more gene therapies in development, we see an increasing need in the industry for scalable manufacturing technologies to enable production of AAV vectors at large scale.”